Previous 10 | Next 10 |
2024-04-10 14:00:03 ET Scott Schoenhaus from BOCOM International Holdings Company issued a price target of $9.00 for GDRX on 2024-04-10 12:10:00. The adjusted price target was set to $9.00. At the time of the announcement, GDRX was trading at $6.92. The overall price tar...
2024-04-10 12:56:01 ET More on Certara, GoodRx Holdings, etc. GoodRx Holdings: Large TAM Continues To Support Growth Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment Wel...
2024-04-10 05:15:02 ET KeyBanc analyst issues OVERWEIGHT recommendation for GDRX on April 10, 2024 01:31AM ET. GDRX was trading at $6.74 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Strong Buy, 6 ...
2024-04-10 05:00:03 ET Scott Schoenhaus from KeyBanc issued a price target of $9.00 for GDRX on 2024-04-10 01:31:00. The adjusted price target was set to $9.00. At the time of the announcement, GDRX was trading at $6.74. The overall price target consensus is at $17.50 wi...
2024-04-05 17:28:37 ET More on GoodRx Holdings GoodRx Holdings: Large TAM Continues To Support Growth GoodRx Holdings, Inc. (GDRX) Q4 2023 Earnings Call Transcript GoodRx: Cost Saving Is A Strong Value Proposition To Consumers Wells Fargo upgrades GoodRx, sto...
2024-04-01 23:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-25 16:24:00 ET Shares of GoodRX (NASDAQ: GDRX) rallied 7.5% today, as the prescription drug price-comparison site and telehealth platform garnered a positive upgrade from analysts at Wells Fargo. Monday's performance continued the stock's strong performance since the beg...
2024-03-25 14:24:38 ET More on GoodRx Holdings GoodRx Holdings: Large TAM Continues To Support Growth GoodRx Holdings, Inc. (GDRX) Q4 2023 Earnings Call Transcript GoodRx: Cost Saving Is A Strong Value Proposition To Consumers GoodRx interim CEO extends commi...
2024-03-25 12:30:02 ET UBS analyst issues UNDERPERFORM recommendation for GDRX on March 25, 2024 11:00AM ET. The previous analyst recommendation was Underperform. GDRX was trading at $7.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-03-25 12:30:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for GDRX on March 25, 2024 11:00AM ET. The previous analyst recommendation was Sector Perform. GDRX was trading at $7.41 at issue of the analyst recommendation. The overall analyst consensus ...
News, Short Squeeze, Breakout and More Instantly...
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® PR Newswire First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and S...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management ...
Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to GoodRx GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the ...